Literature DB >> 21068131

Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2.

Mei-Hsuan Lee1, Hwai-I Yang, Chin-Lan Jen, Sheng-Nan Lu, Shiou-Hwei Yeh, Chun-Jen Liu, San-Lin You, Chien-An Sun, Li-Yu Wang, Wei J Chen, Chien-Jen Chen.   

Abstract

AIM: The aim of this study was to explore the community-level risk factors, such as high hepatitis C viruse (HCV)-RNA positive rate and limited medical resources in a township, for HCV infection, one major cause of liver cirrhosis and hepatocellular carcinoma.
METHODS: This study enrolled 23,820 residents living in 155 villages of seven townships in Taiwan in 1991-2 to explore both individual and community risk factors for HCV infection. Antibodies against HCV (anti-HCV), HCV-RNA and HCV genotype in serum samples were determined by enzyme immunoassay, PCR and melting curve analysis, respectively.
RESULTS: The overall anti-HCV seroprevalence was 5.5%, HCV-RNA was detectable in 68.1% of the seropositives of anti-HCV, and genotype 1 was the most prevalent genotype (54.6%). Personal risk factors for the seropositivity of anti-HCV included older age, female gender, low educational level and history of blood transfusion. Based on the multilevel analysis, persons living in villages with high HCV-RNA-positive rates and limited healthcare resources had an increased seroprevalence of anti-HCV after adjustment for individual risk factors. The multivariate-adjusted prevalence OR (95% CI) was 3.49 (1.80 to 6.76) and 8.48 (5.07 to 14.20) for villages with medium and high HCV-RNA positive rate, respectively. The multivariate-adjusted OR (95% CI) was was 1.75 (0.76 to 4.01) and 3.91 (2.25 to 6.80), respectively, for villages with medium and poor healthcare resources.
CONCLUSIONS: This study suggests that community risk factors contribute significantly to the variation in anti-HCV seroprevalence. It implies both the adequacy of healthcare resources and the treatment of patients positive for HCV-RNA may prevent individual residents from the acquisition of HCV infection from the community.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068131     DOI: 10.1136/gut.2010.220889

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

Review 1.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

2.  Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.

Authors:  Hui-Chen Wu; Hwai-I Yang; Qiao Wang; Chien-Jen Chen; Regina M Santella
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

3.  Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Mei-Hsuan Lee; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

Review 4.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

Review 5.  Protein degradation-associated mechanisms that are affected in Alzheimer´s disease.

Authors:  Angeles C Tecalco-Cruz; José Pedraza-Chaverri; Alfredo Briones-Herrera; Eduardo Cruz-Ramos; Lilia López-Canovas; Jesús Zepeda-Cervantes
Journal:  Mol Cell Biochem       Date:  2022-01-27       Impact factor: 3.396

6.  Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.

Authors:  Yuag-Meng Liu; Yu-Jen Cheng; Yu-Lin Li; Chun-Eng Liu; Wu-Huei Hsu
Journal:  Lung       Date:  2013-11-30       Impact factor: 2.584

Review 7.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

Review 8.  Living donor liver transplantation in Taiwan-challenges beyond surgery.

Authors:  Vinod G Pillai; Chao-Long Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

Review 9.  Epidemiology and natural history of hepatitis C virus infection.

Authors:  Mei-Hsuan Lee; Hwai-I Yang; Yong Yuan; Gilbert L'Italien; Chien-Jen Chen
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

10.  Increased Risk of Age-Related Macular Degeneration with Chronic Hepatitis C Virus Infection: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan.

Authors:  Chih-Ching Yeh; Meei-Maan Wu; Chia-Min Wu; Fung-Chang Sung; Chih-Hsin Muo; Arlene Te; Fu-Hsiung Su
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.